Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A1XG
|
||||
| Former ID |
DNC013126
|
||||
| Drug Name |
YRFB
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H37N7O6
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)CC(C(=O)NCCC(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O<br />)C(CC2=CC=C(C=C2)O)N
|
||||
| InChI |
1S/C27H37N7O6/c28-20(15-18-8-10-19(35)11-9-18)24(38)33-21(7-4-13-32-27(29)30)26(40)34-22(16-17-5-2-1-3-6-17)25(39)31-14-12-23(36)37/h1-3,5-6,8-11,20-22,35H,4,7,12-16,28H2,(H,31,39)(H,33,38)(H,34,40)(H,36,37)(H4,29,30,32)/t20-,21-,22-/m0/s1
|
||||
| InChIKey |
XNBYETXMULNTPG-FKBYEOEOSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.